Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%
Low Eosinophil Patients Have 39% Reduction, Supporting Broad Label
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
You may also be interested in...
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.
In this week's podcast edition of Scrip's Five Must-Know Things, hear about Sanofi’s rebates, Moderna’s business prospects, US views on coronavirus vaccine comparisons, Piot talk about virus variants, and new results for Amgen's asthma drug.
The SOURCE failure is a reversal for the novel Amgen-partnered TSLP inhibitor after NAVIGATOR success last month, and comes just days after the US FDA requested more analyses of the pivotal data for the kidney disease anemia therapy roxadustat.